In support of the theory of CED, Kandasamy et al. demonstrated THC, a CB1/2 agonist, ameliorated the effects of induced migraine in rats, and that this effect was attenuated on administration of a CB1 antagonist [83]. The gene discussed is CNR1; the disease is cranioectodermal dysplasia.